Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $179.00 at Royal Bank of Canada

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price raised by research analysts at Royal Bank of Canada from $175.00 to $179.00 in a report issued on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank of Canada’s price objective suggests a potential upside of 65.66% from the company’s current price.

Other analysts have also recently issued research reports about the company. Needham & Company LLC restated a “buy” rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. UBS Group decreased their price target on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 2nd. Finally, Wells Fargo & Company lowered their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $173.43.

Jazz Pharmaceuticals Trading Down 2.8 %

Shares of Jazz Pharmaceuticals stock opened at $108.05 on Wednesday. The stock has a market capitalization of $6.81 billion, a P/E ratio of 22.28, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $134.48. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The company has a 50-day simple moving average of $111.01 and a 200 day simple moving average of $109.64.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $3.80 by $0.87. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. Research analysts expect that Jazz Pharmaceuticals will post 16.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently bought and sold shares of JAZZ. State of Alaska Department of Revenue increased its position in shares of Jazz Pharmaceuticals by 387.6% in the 3rd quarter. State of Alaska Department of Revenue now owns 33,173 shares of the specialty pharmaceutical company’s stock valued at $3,695,000 after buying an additional 26,370 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Jazz Pharmaceuticals by 37.3% in the third quarter. DekaBank Deutsche Girozentrale now owns 115,130 shares of the specialty pharmaceutical company’s stock valued at $12,641,000 after acquiring an additional 31,283 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Jazz Pharmaceuticals by 15.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,476 shares of the specialty pharmaceutical company’s stock worth $275,000 after acquiring an additional 325 shares in the last quarter. Warther Private Wealth LLC bought a new stake in shares of Jazz Pharmaceuticals in the third quarter worth about $3,700,000. Finally, Tectonic Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 6.3% during the third quarter. Tectonic Advisors LLC now owns 3,891 shares of the specialty pharmaceutical company’s stock worth $433,000 after purchasing an additional 232 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.